development. however it also has licensing agreements with a number of big players. bayer, glaxosmithkline, pfizer among others. and this company is poised to make money from milestone payments on drugs they have. and after today's pull back, got to wonder, maybe there's some room to run, so let's talk to clay segow, president and ceo of seattle genetics. welcome back to "mad money." >> thank you, jim. a pleasure to be back here. >> all right, clay, walk us through, including some of the data that just came out today, that makes seattle genetics more attractive to investors than it was 72 hours ago. >> well, first of all, we put out a lot of data and it really shows that we're helping a diverse set of patients, and that's our goal is to really make a difference in patients'